PHIO PHARMACEUTICALS CORP. Deferred Federal, State and Local, Tax Expense (Benefit)
PHIO PHARMACEUTICALS CORP. (PHIO) reported Deferred Federal, State and Local, Tax Expense (Benefit) of $2.61 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit · last filed 2026-03-05
- PHIO PHARMACEUTICALS CORP. deferred federal, state and local, tax expense (benefit) for fiscal 2025 was $2.61M, a 18.13% increase from fiscal 2024.
- PHIO PHARMACEUTICALS CORP. deferred federal, state and local, tax expense (benefit) for fiscal 2024 was $2.21M, a 13.22% decline from fiscal 2023.
- PHIO PHARMACEUTICALS CORP. deferred federal, state and local, tax expense (benefit) for fiscal 2023 was $2.55M.
- PHIO PHARMACEUTICALS CORP. deferred federal, state and local, tax expense (benefit) for fiscal 2022 was -$2.29M.
| Period end | Deferred Federal, State and Local, Tax Expense (Benefit) 12 month | Deferred Federal, State and Local, Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.61M 10-K · filed 2026-03-05 | |
| 2024-12-31 | $2.21M 10-K · filed 2026-03-05 | -$2.21M 10-K · filed 2025-03-31 |
| 2023-12-31 | $2.55M 10-K · filed 2025-03-31 | -$2.55M 10-K · filed 2024-04-01 |
| 2022-12-31 | -$2.29M 10-K · filed 2024-04-01 | |
| 2021-12-31 | -$4.34M 10-K · filed 2023-03-22 | $4.34M 10-K · filed 2022-03-22 |
| 2020-12-31 | -$15.33M 10-K · filed 2022-03-22 | -$2.64M 10-K · filed 2021-03-25 |
| 2019-12-31 | -$2.53M 10-K · filed 2021-03-25 | |
| 2018-12-31 | -$2.19M 10-K · filed 2020-03-26 | |
| 2017-12-31 | $1.38M 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |